Overview

The objective of this study is to monitor the usage of Lorviqua in real practice within label, including the adverse events associated with Lorviqua

Eligibility

Inclusion Criteria:

        Patients must meet all of the following inclusion criteria to be eligible for inclusion in
        the study:
          1. Use in the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive
             metastatic non-small cell lung cancer (NSCLC)
          2. Evidence of a personally signed and dated informed consent document indicating that
             the patient (or a legally acceptable representative) has been informed of all
             pertinent aspects of the study.
        Exclusion Criteria:
        Patients meeting any of the following criteria will not be included in the study:
          1. Patients to whom Lorviqua® is contraindicated as per the local labeling. A.
             Hypersensitivity to Lorviqua® or to any of the excipients of this product B. Lorviqua®
             is contraindicated in patients taking concomitant use of strong CYP3A4/5 inducers C.
             This medicinal product contains lactose as an excipient. Patients with rare hereditary
             problems of galactose intolerance, total lactase deficiency, or glucose galactose
             malabsorption should not take this medicinal product.
          2. Any patients (or a legally acceptable representative) who does not agree that Pfizer
             and companies working with Pfizer use his/her information